Vaxcyte’s VAX-31 Meets All Key Endpoints in Phase 3 Trial, Setting Stage for FDA Review
Event summary
- Vaxcyte’s VAX-31 met all prespecified primary endpoints in the OPUS-1 Phase 3 trial, including noninferiority and superiority criteria across age groups.
- The vaccine demonstrated a safety profile similar to existing pneumococcal vaccines (PCV20 and PCV21) across all ages studied.
- Vaxcyte plans to report results from OPUS-2 and OPUS-3 trials in the first half of 2027, with a Biologics License Application submission expected in the first half of 2028.
- VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older.
The big picture
Vaxcyte’s positive Phase 3 results for VAX-31 mark a significant step in the race to develop a next-generation pneumococcal vaccine. The broader coverage and robust immune responses demonstrated in the trial could set a new benchmark for the class, addressing critical gaps in adult pneumococcal disease coverage. The strategic anomaly here is the company’s ability to deliver a 31-valent vaccine while maintaining the magnitude of immune responses, a challenge that has limited competitors.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the OPUS-1 data as sufficient for approval, given the stringent noninferiority standards applied.
- Market Positioning
- How VAX-31’s broader coverage and robust immune responses will position it against existing vaccines like PCV20 and PCV21.
- Execution Risk
- The pace at which Vaxcyte can complete the remaining trials and manufacturing consistency studies to meet the 2028 BLA submission timeline.
Related topics
